Pergamum agreed to collaborate with Cadila Pharmaceuticals to develop a new treatment for infections based on a novel targeting mechanism that is different from classical antibiotic therapy.
Study identified a metabolic vulnerability in the aggressive and incurable brain cancer glioblastoma and shown how it can potentially be exploited for therapy.
The success of cell therapies hinges on not only proving that a product elicits the desired biological response, but also overcoming the challenges of manufacturing and administering a complex product to any patient.
Deal signed less than a month before the planned launch of the opioid-induced constipation (OIC) treatment for adults with chronic non-cancer pain.
https://youtu.be/ugXiQqbUNQQ Broadcast Date: June 21st, 2017Time: 11:00 am ET, 8:00 am PT Biophysical and chemical properties are critical factors that can dictate success or failure in the development...
A group of scientists at Texas Biomedical Research Institute have zeroed in on a new defense against HIV-1, the virus that causes AIDS.
Evotec said today it will join Sanofi in partnering with academic institutions to translate their research into new small-molecule drugs across multiple unspecified therapeutic...
A rationally designed drug-like protein interferes with the protein-protein interactions of PCNA, the so-called DNA clamp, offering a new way of hindering DNA replication in fast-proliferating cancer cells.
Through the acquisition, Otsuka will inherit Visterra’s Hierotope® platform, intended to design and engineer precision antibody-based therapies, and expand its pipeline with Visterra’s programs targeting infectious diseases, kidney diseases, cancer, and chronic pain.